New cancer drug enters human testing for Tough-to-Treat tumors
NCT ID NCT07281326
Summary
This early-stage study is testing a new drug called AK138D1 in people with advanced solid cancers that haven't responded to standard treatments. Researchers will give the drug to up to 200 participants to find the safest dose and see if it shows any signs of fighting their cancer. The main goal is to understand how the body handles the drug and what side effects it might cause.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact
Conditions
Explore the condition pages connected to this study.